1. Introduction {#sec1-ijerph-15-02889}
===============

Lung cancer is recognized as the leading cause of cancer deaths around the globe \[[@B1-ijerph-15-02889]\]. In the USA, it accounts for 27% of cancer-related mortalities, killing more than 85,000 victims in a single year \[[@B2-ijerph-15-02889]\]. Part of lung cancer lethality is a result of its late diagnosis, as over half of lung cancer cases are diagnosed with distant metastasis \[[@B1-ijerph-15-02889]\]. Therefore, the importance of screening for early stages of lung cancer cannot be overemphasized. Since the 1990s, clinical trials and research on lung cancer screening have flourished \[[@B3-ijerph-15-02889]\], and several guidelines have also been established for effective screening \[[@B4-ijerph-15-02889]\]. However, screening efficacy in different countries or regions is seldom compared, and screening studies often fail to use credible tools. By contrast, smoking cessation programs unequivocally contribute to reduced cancer risk and improved prognosis in lung cancer patients \[[@B5-ijerph-15-02889],[@B6-ijerph-15-02889],[@B7-ijerph-15-02889]\]. Regardless, the institution of these favorable policies relies on a good health care system.

One innovative parameter for evaluating the prognosis of a specific disease is the mortality-to-incidence ratio (MIR). The value of one-(MIR) also approximates the five-year survival for most cancers \[[@B8-ijerph-15-02889]\]. Parkin and Bray showed the significance of the MIR for the completeness of cancer registries in terms of the quality of cancer care \[[@B9-ijerph-15-02889]\]. In 2015, Sunkara et al. found a positive correlation between the MIRs for colorectal cancer in different countries and those countries' health care system rankings, indicating that the MIR could be a potential parameter for evaluating cancer surveillance programs \[[@B10-ijerph-15-02889]\]. Overall, the MIR value for a given country depends on that country's screening policies, which are limited in turn by the state of the country's health care system.

Screening for colorectal cancer is much simpler and less costly than screening for lung cancer; a much deadlier disease. Therefore, the aim of our study was to determine whether the MIR for lung cancer also shows a relationship with parameters such as total expenditures on health/gross domestic product (e/GDP) and the World Health Organization (WHO) rankings among different countries, regions, and continents.

2. Methods {#sec2-ijerph-15-02889}
==========

Data acquisition was described previously \[[@B11-ijerph-15-02889],[@B12-ijerph-15-02889],[@B13-ijerph-15-02889]\]. In brief, cancer incidence and mortality data including the numbers, crude rates, and age-standardized rates (ASR) were obtained from the GLOBOCAN 2012 database (<http://globocan.iarc.fr/Default.aspx>), which is maintained by the International Agency for Research on Cancer, IARC (<https://www.iarc.fr/>). The definitions are described in the IARC website (<http://www-dep.iarc.fr/WHOdb/glossary.htm>). The WHO rankings were obtained from the World's Health Systems of WHO. Health expenditures and life expectancies were obtained from the World Health Statistics of WHO (<https://www.who.int/gho/publications/world_health_statistics/en/>).

The GLOBOCAN 2012 database contains data from 184 countries. We excluded countries that lacked WHO ranking data (22 countries), or those that had a low availability level of the data (ranking E to G for incidence or ranking 4 to 6 for mortality; 105 countries). Ultimately, 57 countries were included in the analyses. The MIR was defined previously as the ratio of the crude rate of mortality to the incidence \[[@B10-ijerph-15-02889],[@B11-ijerph-15-02889],[@B12-ijerph-15-02889],[@B13-ijerph-15-02889]\].

The statistical analysis methods were described previously \[[@B11-ijerph-15-02889],[@B12-ijerph-15-02889],[@B13-ijerph-15-02889]\]. We evaluated the association between the MIRs and variants by linear regression and bivariate correlation using the Spearman correlation test and SPSS statistical software version 15.0 (SPSS, Inc., Chicago, IL, USA). *p* values \<0.05 were considered statistically significant. Scatter plots were produced using Microsoft Excel 2010. The data sets analyzed during the current study will be made available upon request.

Ethics Approval and Consent to Participate
------------------------------------------

Not applicable. All the data were obtained from the global statistics of GLOBOCAN (<http://globocan.iarc.fr/Default.aspx>). This is a study of analytic epidemiology, and we did not perform any intervention on human participants. We confirm that this study complied with national guidelines (<http://law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0020162>).

3. Results {#sec3-ijerph-15-02889}
==========

3.1. Crude Rates of Incidence/Mortality According to Regions {#sec3dot1-ijerph-15-02889}
------------------------------------------------------------

The crude rates of incidence and mortality for lung cancer in different regions of the world are summarized in [Table 1](#ijerph-15-02889-t001){ref-type="table"}. These regions were grouped by development status, WHO region categories, and continents. When standardized by patient age, the incidence and mortality rates around the world were 23.1 and 19.7, respectively, for a MIR of 0.87. When compared with less developed regions, the more developed regions had much higher crude rates of incidence and mortality (60.9 and 50.3, respectively for more developed vs. 18.4 and 16.6, respectively for less developed). However, the MIR was markedly lower for the more developed regions (0.83 vs. 0.90, respectively). In terms of the WHO region categories, the European region had the highest mortality and incidence crude rates (49.7 and 43.0, respectively), while the African region had the lowest (2.1 and 1.7, respectively). The region with the lowest MIR was the Americas (0.81), and that with the highest was Southeast-Asia (0.91). When categorized by continents, Africa had the lowest incidence and crude mortality rates (2.8 and 2.5, respectively), while North America had the highest (68.4 and 53.5, respectively). Three continents shared the highest MIR of 0.89 (Africa, Latin-America, and the Caribbean), while Oceania had the lowest MIR (0.75).

3.2. Crude rates of Incidence/Mortality and Case Numbers of Incidence/Mortality According to Countries {#sec3dot2-ijerph-15-02889}
------------------------------------------------------------------------------------------------------

[Table 2](#ijerph-15-02889-t002){ref-type="table"} summarizes the lung cancer crude rates of incidence and mortality according to countries. The five counties with a crude rate of incidence greater than 70 were Japan (75.0), the Netherlands (71.6), Belgium (72.2), Canada (73.5), and Denmark (81.6). Three of these five countries were also among those with a crude mortality rate over 60, with Japan (59.4) and Canada (58.0) as exceptions. The other country with a mortality rate over 60 was Poland (61.0).

3.3. MIRs According to Countries {#sec3dot3-ijerph-15-02889}
--------------------------------

The calculated MIRs are also presented in [Table 2](#ijerph-15-02889-t002){ref-type="table"}. The three countries with MIRs over 1.00 were Mauritius (1.37), Estonia (1.05), and Ecuador (1.01). Countries with the lowest MIRs, below 0.75, were Switzerland (0.75), Australia (0.73), and Costa Rica (0.70).

3.4. The Association between WHO Ranking, e/GDP, and MIR among Countries {#sec3dot4-ijerph-15-02889}
------------------------------------------------------------------------

[Supplementary Figures S1 and S2](#app1-ijerph-15-02889){ref-type="app"} show the linear correlation between the WHO ranking, e/GDP, and the crude and age-standardized mortality and incidence rates for different countries. When standardized by age, the crude incidence rates maintained a correlation with WHO ranking, whereas the correlation that was evident between the mortality rate and WHO ranking before standardization disappeared after standardization. Conversely, the positive correlation between e/GDP, crude incidence, and crude mortality rates for different countries remained significant even after standardization. [Figure 1](#ijerph-15-02889-f001){ref-type="fig"} shows the scatter plot for MIR, WHO ranking ([Figure 1](#ijerph-15-02889-f001){ref-type="fig"}A), and e/GDP ([Figure 1](#ijerph-15-02889-f001){ref-type="fig"}B) among the different countries. We found a positive correlation between the MIRs and WHO rankings (regression coefficient: 0.001; 95% confidence interval: \<0.001 to 0.002; R^2^ = 0.14, *p* value = 0.014; for the Spearman correlation test: Correlation coefficient = 0.340, *p* value = 0.010), indicating that a better healthcare ranking led to a lower MIR. Linear regression and bivariate correlation using the Spearman correlation test also indicated a correlation between the MIRs and e/GDP (regression coefficient: −0.014; 95% confidence interval: −0.024 to −0.005; R^2^ = 0.144, *p* value = 0.004; for the Spearman correlation test: Correlation coefficient = 0.421, *p* value = 0.001). The MIRs were better for countries with higher e/GDP.

4. Discussion {#sec4-ijerph-15-02889}
=============

We found a significant correlation between the WHO rankings and the MIR for lung cancer in different countries. In general, the MIR decreased as the ranking improved. Therefore, although lung cancer and colon cancer differ in their characteristics, the negative correlation found by Sunkara et al. for MIR and colon cancer is still applicable to lung cancer \[[@B10-ijerph-15-02889]\]. This consistent correlation could reflect the abundance of tools now available for lung cancer screening in countries with better health care rankings.

Low dose computed tomography (LDCT) has now become a vital component in lung cancer screening, as detection of non-calcified lung nodules is ten times more frequent with LDCT than with chest X-rays \[[@B14-ijerph-15-02889]\]. The use of LDCT in a national lung screening trial also resulted in a significant increase in the incidence rate, and a 20% reduction in the mortality rate when compared to chest X-ray screening \[[@B15-ijerph-15-02889]\]. Another powerful and novel screening alternative is the use of molecular biomarkers for screening to detect early stage cases for timely treatment \[[@B16-ijerph-15-02889]\]. These relatively new and more effective screening methods are more readily available in countries with better healthcare rankings. Early detection, in combination with effective treatment, brings about the association we have demonstrated here. The association of MIR with eGDP is compatible with that of the WHO healthcare ranking. This is understandable, since a fair financial contribution is an important element of the ranking system.

Public health policy also plays an important role in disease prevention and would contribute to the correlation between the WHO rankings and the lung cancer MIR. For example, smoking cessation has substantial general health benefits, including reduction of cancer incidence and mortality. With respect to lung cancer specifically, smoking is the primary causal factor, and cessation clearly and unequivocally reduces the risk of lung cancer \[[@B6-ijerph-15-02889]\]. In a historical cohort studied over 33 years, smoking cessation sharply reduced lung cancer mortality in lung cancer patients \[[@B7-ijerph-15-02889]\]. Consequently, quitting smoking and offering smoking cessation interventions are recommended \[[@B5-ijerph-15-02889]\]. However, financial and health care system support are necessary for smoking cessation programs, so countries with better WHO rankings would again be expected to have favorable MIRs for lung cancer, as demonstrated here.

The association between the crude mortality rate and the WHO ranking is somewhat disturbing. However, this association is expected, since we used the crude mortality rate instead of the disease mortality rate. The higher incidence rates in better-ranked countries result in more lung cancer cases and higher crude mortality rates. Age may have also been a cause of the outcome, since people in countries with better rankings are more likely to have longer life expectancies than those in countries with worse rankings, and this would again contribute to higher cancer mortalities. This life expectancy effect could also explain the non-significant result with an age-standardized crude mortality rate.

To our knowledge, this is the first article to address the association between the MIR of lung cancer, the WHO ranking, and e/GDP. However, our study also has some limitations. We did not include countries with poor data quality or with no available data quality assessment, which might result in misleading MIRs. The result is incompleteness of the data collection and reduction in the generalizability of the results to, for example, under-represented countries from Africa. Furthermore, we did not record the additional risk factors, such as smoking percentages, asbestos exposures, and particulate matter 2.5 pollution among the different countries. These risk factors may play important roles in determining the incidence and mortality rates among countries and regions \[[@B17-ijerph-15-02889],[@B18-ijerph-15-02889]\]. We also collected the cross-sectional data for only one year, so these data may not accurately depict the actual trend of the disease and may not allow inference of causality. Another limitation is the use of the WHO ranking; this ranking was established in 2000, so it may not precisely represent the current situation for health care systems among different countries.

Despite these limitations, our study shows higher incidence and mortality rates for lung cancer in more developed regions and in countries with better WHO rankings. The MIRs of different countries were also negatively correlated with the WHO rankings. The MIR is therefore a potentially useful parameter for evaluating the screening and healthcare treatment status for lung cancer.

5. Conclusions {#sec5-ijerph-15-02889}
==============

The MIR for lung cancer varies with the expenditure on health and the ranking of health systems, making it a potentially useful parameter for global evaluation of the clinical outcomes for lung cancer.

The following are available online at <http://www.mdpi.com/1660-4601/15/12/2889/s1>, Figure S1: Countries with good World Health Organization rankings have high crude rates of (A) incidence, and (B) mortality, as well as high age-standardized rates (ASR) of (C) incidence. The association between World Health Organization rankings and the ASR of (D) mortality was not statistically significant, Figure S2: Countries with good World Health Organization rankings have high crude rates of (A) incidence, and (B) mortality, as well as high age-standardized rates (ASR) of (C) incidence, and (D) mortality.
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![The (**A**) World Health Organization rankings and (**B**) total expenditures on health/GDP were associated with the mortality-to-incidence ratio (MIR) for lung cancer. The *p* value was determined by bivariate correlation using the Spearman correlation test. The country with an extreme value is Mauritius (MIR = 1.38).](ijerph-15-02889-g001){#ijerph-15-02889-f001}
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###### 

Summary of the case number, rates, and mortality-to-incidence ratio of the incidence and mortality according to regions in lung cancer.

  Region                            Number      Crude Rate ^1^   Age-Standardized Rate ^1^   Mortality-to-Incidence Ratio ^2^                 
  --------------------------------- ----------- ---------------- --------------------------- ---------------------------------- ------ ------ ------
  World                             1,824,701   1,589,925        25.9                        22.5                               23.1   19.7   0.87
  Development                                                                                                                                 
    More developed regions          758,214     626,570          60.9                        50.3                               30.8   24.2   0.83
    Less developed regions          1,066,487   963,355          18.4                        16.6                               20.0   18.0   0.90
  WHO region categories                                                                                                                       
    WHO Africa region               18,051      16,108           2.1                         1.8                                3.9    3.5    0.86
    WHO Americas region             324,301     262,314          34.0                        27.5                               26.0   20.4   0.81
    WHO East Mediterranean region   32,542      28,977           5.2                         4.7                                7.9    7.1    0.90
    WHO Europe region               448,618     388,203          49.7                        43.0                               28.7   24.0   0.87
    WHO South-East Asia region      162,003     146,216          8.7                         7.9                                10.5   9.5    0.91
    WHO Western Pacific region      838,978     747,920          45.5                        40.6                               32.8   28.5   0.89
  Continent                                                                                                                                   
    Africa                          30,314      27,083           2.8                         2.5                                5.0    4.5    0.89
    Latin America and Caribbean     84,520      74,602           14.0                        12.4                               13.7   12.0   0.89
    Northern America                239,781     187,712          68.4                        53.5                               38.3   28.6   0.78
    Asia                            1,045,695   936,051          24.6                        22.0                               23.4   20.7   0.89
    Europe                          410,220     353,848          55.3                        47.7                               29.0   24.0   0.86
    Oceania                         14,171      10,629           37.6                        28.2                               25.3   18.3   0.75

^1^ per 100,000 population; ^2^ the percentage in the ratio of the crude rate of mortalities and the crude rate of incidences.
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###### 

Summary of World Health Organization rankings, total expenditure on health/GDP, life expectancy, lung cancer incidence, mortality, and mortality-to-incidence ratio of selected countries.

  Country                    Ranking   Total Expenditure on Health/GDP (%)   Life Expectancy ^1^   Number    Crude Rate ^2^   Age-Standardized Rate ^2^   Mortality-to-Incidence Ratio ^3^                 
  -------------------------- --------- ------------------------------------- --------------------- --------- ---------------- --------------------------- ---------------------------------- ------ ------ ------
  France                     1         11.6                                  82                    40,043    31,434           63.1                        49.5                               35.0   25.3   0.78
  Italy                      2         9.2                                   83                    37,238    33,531           61.1                        55.0                               24.5   20.7   0.90
  Malta                      5         8.7                                   81                    181       139              43.2                        33.2                               20.4   15.6   0.77
  Singapore                  6         4.2                                   83                    1974      1590             37.6                        30.2                               24.9   19.8   0.80
  Spain                      7         9.3                                   83                    26,715    21,118           57.1                        45.2                               30.3   22.8   0.79
  Oman                       8         2.7                                   76                    76        70               2.6                         2.4                                5.1    4.8    0.92
  Austria                    9         11.1                                  81                    4576      3658             54.3                        43.4                               27.5   20.7   0.80
  Japan                      10        10.3                                  84                    94,855    75,119           75.0                        59.4                               24.6   17.4   0.79
  Norway                     11        9.3                                   82                    2845      2219             57.4                        44.7                               30.0   22.2   0.78
  Portugal                   12        9.9                                   81                    4192      3441             39.2                        32.2                               20.2   15.7   0.82
  Iceland                    15        9.0                                   82                    162       141              49.3                        42.9                               29.8   24.5   0.87
  Luxembourg                 16        7.2                                   82                    261       218              49.9                        41.7                               28.4   23.1   0.84
  Netherlands                17        12.7                                  81                    11,968    10,609           71.6                        63.5                               37.2   30.5   0.89
  United Kingdom             18        9.3                                   81                    40,382    35,581           64.3                        56.7                               30.0   25.4   0.88
  Ireland                    19        8.9                                   81                    2273      1778             49.6                        38.8                               31.3   23.6   0.78
  Switzerland                20        11.4                                  83                    4237      3194             54.8                        41.3                               27.3   20.0   0.75
  Belgium                    21        10.9                                  80                    7794      7179             72.2                        66.5                               36.8   30.5   0.92
  Colombia                   22        6.8                                   78                    4780      4417             10.1                        9.3                                11.0   10.1   0.92
  Sweden                     23        9.6                                   82                    3891      3695             41.0                        38.9                               19.1   16.4   0.95
  Cyprus                     24        7.3                                   82                    276       258              24.4                        22.8                               16.2   14.7   0.93
  Germany                    25        11.3                                  81                    50,813    43,420           62.0                        53.0                               27.5   22.2   0.85
  Israel                     28        7.4                                   82                    2270      1956             29.5                        25.4                               21.2   17.9   0.86
  Canada                     30        10.9                                  82                    25,481    20,108           73.5                        58.0                               37.9   28.4   0.79
  Finland                    31        9.1                                   81                    2494      2138             46.2                        39.6                               20.1   16.7   0.86
  Australia                  32        8.9                                   83                    11,331    8232             49.4                        35.9                               27.0   18.5   0.73
  Chile                      33        7.3                                   80                    3127      2980             17.9                        17.1                               13.3   12.5   0.96
  Denmark                    34        11.0                                  80                    4566      3806             81.6                        68.1                               39.2   31.4   0.83
  Costa Rica                 36        10.1                                  79                    363       256              7.6                         5.3                                7.3    5.1    0.70
  United States of America   37        17.0                                  79                    214,226   167,545          67.8                        53.1                               38.4   28.6   0.78
  Slovenia                   38        9.4                                   80                    1360      1131             66.7                        55.4                               33.9   26.8   0.83
  Cuba                       39        8.6                                   78                    6143      5763             54.6                        51.2                               32.9   30.1   0.94
  New Zealand                41        10.2                                  82                    2027      1659             45.4                        37.2                               25.9   20.8   0.82
  Bahrain                    46        4.4                                   77                    84        64               6.2                         4.7                                15.5   12.4   0.76
  Thailand                   47        4.5                                   75                    19,505    17,669           27.9                        25.3                               20.9   19.1   0.91
  Czech Republic             48        7.5                                   78                    6683      5228             63.3                        49.5                               32.5   24.7   0.78
  Malaysia                   49        4.0                                   74                    4403      4134             15.0                        14.1                               17.9   17.0   0.94
  Poland                     50        6.8                                   77                    26,230    23,371           68.5                        61.0                               38.0   33.4   0.89
  Jamaica                    53        5.6                                   74                    512       460              18.5                        16.7                               18.2   15.8   0.90
  Korea, Republic of         58        7.6                                   82                    22,873    17,848           47.1                        36.7                               28.7   21.3   0.78
  Philippines                60        4.4                                   69                    12,074    10,369           12.5                        10.7                               19.3   17.0   0.86
  Slovakia                   62        8.1                                   76                    2531      1981             46.2                        36.1                               28.3   21.6   0.78
  Egypt                      63        4.9                                   71                    5017      4488             6.0                         5.3                                7.2    6.5    0.88
  Uruguay                    65        8.6                                   77                    1411      1336             41.6                        39.4                               27.4   25.1   0.95
  Trinidad and Tobago        67        5.5                                   71                    184       165              13.6                        12.2                               12.2   10.8   0.90
  Belarus                    72        5.0                                   72                    4012      3422             42.1                        35.9                               26.2   22.1   0.85
  Lithuania                  73        6.7                                   74                    1555      1292             47.2                        39.2                               26.2   21.2   0.83
  Argentina                  75        6.8                                   76                    11,244    10,531           27.3                        25.6                               20.9   19.1   0.94
  Estonia                    77        5.9                                   77                    632       665              47.2                        49.6                               24.4   23.6   1.05
  Ukraine                    79        7.5                                   71                    17,251    14,270           38.4                        31.8                               22.2   18.5   0.83
  Mauritius                  84        4.8                                   74                    149       204              11.3                        15.5                               9.9    13.4   1.37
  Fiji                       96        4.0                                   70                    45        39               5.1                         4.5                                6.0    5.1    0.88
  Bulgaria                   102       7.4                                   75                    3936      3659             53.2                        49.5                               28.1   25.9   0.93
  Latvia                     105       5.9                                   74                    1183      1002             52.9                        44.8                               27.8   22.2   0.85
  Ecuador                    111       6.4                                   76                    1035      1057             7.0                         7.1                                7.2    7.2    1.01
  Brazil                     125       9.5                                   75                    34,280    28,285           17.3                        14.3                               16.3   13.3   0.83
  Russian Federation         130       6.5                                   69                    55,805    50,888           39.1                        35.7                               24.0   21.5   0.91
  South African Republic     175       8.9                                   60                    7242      6465             14.3                        12.7                               18.5   16.7   0.89

^1^ year; ^2^ per 100,000 population; ^3^ the percentage in the ratio of the crude rate of mortalities and the crude rate of incidences.

[^1]: Cheng-Yu Huang and Kwong-Kwok Au contribute equally in this manuscript.
